• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LTRN

    Lantern Pharma Inc.

    Subscribe to $LTRN
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: lanternpharma.com

    Peers

    $SLRX

    Recent Analyst Ratings for Lantern Pharma Inc.

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    See more ratings

    Lantern Pharma Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

      Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern's Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-of-care chemotherapy. Importantly, the patient continues to show sustained survival benefits after nearly two years. The patient, who had previously failed three lines of prior therapy including Keytruda (pembrolizumab) with

      6/16/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

      Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trial Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, today announced promising preclinical data for LP-184 in atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer. The results were presented by Dr. Eric Raabe of Johns Hopkins University School of Medicine at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Co

      5/29/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

      Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

      5/15/25 8:45:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

      Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression. The FDA has cleared the LP-184 investigational new drug (IND) application amendment for the treatment of a biomarker defined patient population of non-small cell lung cancer (NSCLC). The planned phase 1b/2 clinical trial plans to evaluate LP-184 in advanced NSCLC patients with KEAP1 and/or STK11 mutations and low expression of PD-L1 in combination with the immune checkpoint inhibitor therapies, nivolumab and ipilimumab. LP-184 is a synthetically lethal, novel small molecule advanced and developed with La

      5/12/25 9:00:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

      Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

      5/8/25 8:30:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

      The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern's AI platform, RADR® The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib. This achievement follows the FDA's Orphan Drug Designation for LP-184 in TNBC in 2023 and FDA Fast Track Designation for LP-184 in TNBC in 2024. The average survival for newly diagnosed, metastatic TNBC is estimated at 18 months and presents an annual market opportunity in excess of $4 billion USD.  Lantern Pharma Inc. (NASDAQ:LTRN), an artifi

      5/5/25 8:55:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

      HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

      3/27/25 4:01:00 PM ET
      $ACTU
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

      Webcast to be held Thursday, March 27th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2024 operating and financial results webcast on Thursday, March 27, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2024 and provide guida

      3/20/25 8:00:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

      Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability. The application received a favorable PCT search report indicating no significant prior art, substantially strengthening its path to approval. The technology has demonstrated to-date exceptional performance in predicting BBB permeability across a wide range of chemical compounds, processing up to 100,000 molecul

      2/19/25 8:00:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

      Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR® AI platform to accelerate and optimize the development of antibody-drug conjugates (ADCs). The global ADC market is projected to reach $30.4 billion by 2028, growing at a CAGR of 41.7%, with several recently approved ADCs achieving blockbuster status with annual sales exceeding $1 billion. Major biotech and pharmaceutical companies have recently completed ADC-focused acquisitions valued at over $10 billion, highlighting the sect

      1/27/25 7:55:00 AM ET
      $LTRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Lantern Pharma Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Lantern Pharma Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more